Ruthenium antimetastatic agents

Current Topics in Medicinal Chemistry

Volumn 4, Issue 15, 2004, Pages 1525-1535

  Alessio, Enzo ^a   Mestroni, Giovanni ^a   Bergamo, Aberta ^b   Sava, Gianni ^a,b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Callerio Foundation   (Italy)

Author keywords

Anticancer; Antimetastatic; Dimethylsulfoxide; Inorganic medicinal chemistry; Ruthenium

Indexed keywords

ANTIMETASTATIC AGENT; BRIDGED COMPOUND; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLINE; CYSTEINE; DIMER; DIMETHYL SULFOXIDE; GELATINASE B; HETEROCYCLIC COMPOUND; IMIDAZOLE; LIGAND; MATRIX METALLOPROTEINASE; MONOMER; RUTHENIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; BREAST CARCINOMA; CANCER INVASION; CELL CYCLE; CLINICAL TRIAL; COMPLEX FORMATION; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; IC 50; LD 50; LEWIS CARCINOMA; LUNG METASTASIS; NONHUMAN; ONCOLOGICAL PARAMETERS; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DIMETHYL SULFOXIDE; HUMANS; LIGANDS; MOLECULAR CONFORMATION; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; RUTHENIUM;

EID: 10844269461     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387421     Document Type: Review

References (67)

1. Clarke, M. J.; Zhu, F.; Frasca, D. NOD-Platinum Chemotherapeutic Metallopharmaceuticals. Chem. Rev. 1999, 99, 251-2533.
2. Clarke, M. J. Ruthenium Metallopharmaceuticals. Coord. Chem. Rev. 2003, 236, 209-233.
3. Clarke, M. J. Oncological Implications of the Chemistry of Ruthenium. In Metal Ions in Biological Systems; Sigel, H.; Ed.; Marcel Dekker, Inc.: New York, 1980; Vol. 11, pp. 231-283.
4. Mestroni, G.; Alessio, E.; Calligaris, M.; Attia, W. M.; Quadrifoglio, F.; Cauci, S.; Sava, G.; Zorzet, S.; Pacor, S.; Monti-Bragadin, C.; Tamaro, M.; Dolzani, L. Chemical, Biological and Antitumor Properties of Ruthenium(II) Complexes with Dimethylsulfoxide. In Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy; Clarke, M. J.; Ed.; Springer-Verlag: Heidelberg, 1989 pp. 74-88.
5. Mestroni, G.; Alessio, E.; Sava, G.; Pacor, S.; Coluccia, M. The Development of Tumor-Inhibiting Ruthenium Dimethylsulfoxide Complexes. In Metal Complexes in Cancer Chemotherapy; Keppler, B. K.; Ed.; VCH: Weinheim (Germany), 1993, pp. 157-185.
6. Keppler, B. K.; Lipponer, K.-G.; Stenzel, B.; Kratz, F. New Tumor-Inhibiting Ruthenium Complexes. In Metal Complexes in Cancer Chemotherapy; Keppler, B. K.; Ed.; VCH: Weinheim (Germany), 1993 pp. 187-220.
7. Mestroni, G.; Alessio, E.; Sava, G.; Pacor, S.; Coluccia, M.; Boccarelli, A. Water-Soluble Ruthenium(III)-Dimethylsulfoxide Complexes: Chemical Behaviour and Pharmaceutical Properties. Metal-Based Drugs 1994, 1, 41-63.
8. Sava, G.; Alessio, E.; Bergamo, A.; Mestroni, G. Sulfoxide Ruthenium Complexes: Non-Toxic Tools for the Selective Treatment of Solid Tumor Metastases. In Topics in Biological Inorganic Chemistry; Clarke, M. J.; Sadler, P. J.; Eds.; Springer-Verlag: Berlin, 1999; pp 143-169.
9. Morris, R. E.; Aird, R. E.; Murdoch, P. d. S.; Chen, H.; Cummings, J.; Hughes, N. D.; Parsons, S.; Parkin, A.; Boyd, G.; Jodrell, D. I.; Sadler, P. J. Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes. J. Med. Chem. 2001, 44, 3616-3621.
10. Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J. In Vitro and In Vivo Activity and Cross Resistance Profiles of Novel Ruthenium(II) Organometallic Arene Complexes in Human Ovarian Cancer. Br. J. Cancer 2002, 86 1652-1657.
11. Chen, H.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J. Highly Selective Binding of Organometallic Ruthenium Ethylendiamine Complexes to Nucleic Acids: Novel Recognition Mechanisms. J. Am. Chem. Soc. 2003, 125, 173-186.
12. Velders, A. H.; Kooijman, H.; Spek, A. L.; Haasnoot, J. G.; De Vos, D.; Reedijk, J. Strong Differences in the In Vitro Cytotoxicity of Three Isomeric Dichlorobis(2-phenylazopyridine)ruthenium(II) Complexes. Inorg. Chem. 2000, 39, 2966-2967.
13. Hotze, A. C. G.; Bacac, M.; Velders, A. H.; Jansen, B. A. J.; Kooijman, H.; Spek, A. L.; Haasnoot, J. G.; Reedijk, J. New Cytotoxic and Water-Soluble Bis(2-phenylazopyridine)ruthenium (II) Complexes. J. Med. Chem. 2003, 46, 1743-1750.
14. Sava, G.; Bergamo, A. Ruthenium-Based Compounds and Tumor Growth Control (Review). Int. J. Oncol. 2000, 17: 353-365.
15. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium Anticancer Drugs. In Metal Ions in Biological Systems; Sigel, A.; Sigel, H.; Eds., M. Dekker, New York, Vol. 42, 2004, pp. 323-351.
16. Bergamo, A.; Gagliardi, R.; Scarcia, V.; Furlani, A.; Alessio, E.;, Mestroni, G.; Sava, G. In Vitro Cell Cycle Arrest, In Vivo Action on Solid Metastasizing Tumors and Host Toxicity of the Antimetastatic Drug NAMI-A and Cisplatin. J. Pharmacol. Exp. Ther. 1999, 289, 559-564.
17. Pacor, S.; Vadori, M.; Vita, F.; Bacac, M.; Soranzo, M. R.; Zabucchi, G.; Sava, G. Isolation of a Murine Metastatic Cell Line and Preliminary Test of Sensitivity to the Anti-Metastasis Agent NAMI-A. Anticancer Res. 2001, 21, 2523-2530.
18. Morbidelli, L.; Donnini, S.; Filippi, S.; Messori, L.; Piccioli, F.; Orioli, P.; Sava, G.; Ziche, M. Antiangiogenic Properties of Selected Ruthenium(III) Complexes That are Nitric Oxide Scavengers. Br. J. Cancer 2003, 88, 1484-1491.
19. Vacca, A.; Bruno, M.; Boccarelli, A.; Coluccia, M.; Ribatti, D.; Bergamo, A.; Garbisa, S.; Sartor, L.; Sava, G. Inhibition of Endothelial Cell Functions and of Angiogenesis by the Metastasis Inhibitor NAMI-A. Br. J. Cancer 2002, 86, 993-998.
20. Sanna, B.; Debidda, M.; Pintus, G.; Tadolini, B.; Posadino, A.M.; Bennardini, F.; Sava, G.; Ventura, C. The Anti-Metastasis Agent Imidazolium Transimidazoledimehtylsulfoxide-tetrachlororuthenate Induces Endothelial Cell Apoptosis by Inhibiting the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling Pathway. Arch. Biochim. Biophys. 2002, 403, 209-218.
21. Pintus, G.; Tadolini B.; Posadino A.M.; Sanna, B.; Debidda, M.; Bennardini, F.; Sava, G.; Ventura, C. Inhibition of the MEK/ERK Signaling Pathway by the Novel Antimetastatic Agent NAMI-A Down Regulates c-myc Gene Expression and Endothelial Cell Proliferation. Eur. J. Biochem. 2002, 269, 5861-5870.
22. Debidda, M.; Sanna, B.; Cossu, A.; Posadino, A.M.; Tadolini, B.; Ventura, C.; Pintus, G. NAMI-A Inhibits the PMA-Induced ODC Gene Expression in ECV304 Cells: Involvement of PKC/Raf/Mek/ERK Signalling Pathway. Int. J. Oncol. 2003, 23, 477-482.
23. Debidda, M.; Sanna, B.; Cossu, A.; Posadino, A.M.; Tadolini, B.; Ventura, C.; Pintus, G. NAMI-A Inhibits the PMA-Induced ODC Gene Expression in ECV304 Cells: Involvement of PKC/Raf/Mek/ERK Signalling Pathway. Int. J. Oncol. 2003, 23, 477-482.
24. Bacac, M.; Hotze, A. C. G.; van der Schilden, K.; Haasnoot, J. G.; Pacor, S.; Alessio, E.; Sava, G.; Reedijk, J. The Hydrolysis of the Anti-Cancer Ruthenium Complex NAMI-A Affects its DNA Binding and Antimetastatic Activity: an NMR Evaluation. J. Inorg. Biochem. 2004, 98, 402-412.
25. Messori, L.; Orioli, P.; Vullo, D.; Alessio, E.; Iengo, E. A Spectroscopic Study of the Reaction of NAMI, a Novel Ruthenium(III) Anti-Neoplastic Complex, with Bovine Serum Albumin. Eur. J. Biochem. 2000, 267 1206-1213.
26. Sava, G.; Bergamo, A.; Zorzet, S.; Gava, B,; Casarsa, C.; Cocchietto, M.; Furlani, A.; Scarcia, V.; Serli, B.; Iengo, E.; Alessio, E.; Mestroni, G. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur. J. Cancer 2002 38, 427-435.
27. 4]. Russian J. Inorg. Chem. 1992, 37, 1286-1291.
28. Alessio, E.; Milani, B.; Mestroni, G.; Calligaris, M.; Faleschini P.; Attia, W. M. Synthesis and Characterization of New Halogen-Tetramethylenesulfoxide-Ruthenium(II) and Ruthenium (III) Complexes; Crystal Structure of cis-Dichlorotetrakis (tetramethylenesulfoxide)ruthenium(II) and Hydrogen trans-Bis (tetramethylenesulfoxide)tetrachlororuthenate(III). Inorg. Chim. Acta 1990, 177, 255-265.
29. Sava, G.; Pacor, S.; Bergamo, A.; Cocchietto, M.; Mestroni, G.; Alessio, E. Effects of Ruthenium Complexes on Experimental Tumors: Irrelevance of Cytotoxicity for Metastasis Inhibition. Chem.-Biol. Interact. 1995, 95, 109-126.
30. 3). Inorg. Chim. Acta, 1993, 203, 205-217.
31. 2SO-S (Him)]. J. Chem. Soc., Dalton Trans. 1999, 3361-3371.
32. Bergamo, A.; Gava, B.; Alessio, E.; Mestroni, G.; Serli, B.; Cocchietto, M.; Zorzet, S.; Sava, G. Ruthenium-Based NAMI-A Type Complexes with In Vivo Selective Metastasis Reduction and In Vitro Invasion Inhibition Unrelated to Cell Cytotoxicity. Int. J. Oncol. 2002, 21, 1331-1338.
33. Chambers, A. F.; Matrisian, L. M. Changing Views of the Role of Matrix Metallo Proteinases in Metastasis. J. Natl. Cancer Inst. 1997, 89, 1260-1270.
34. Albini, A. Tumor and Endothelial Cell Invasion of Basement Membranes. Path. Oncol. Res. 1998, 40, 230-241.
35. Shapiro, S. D. Matrix Metalloproteinase Degradation of Extracellular Matrix: Biological Consequences. Curr. Opin. Cell. Biol. 1998, 10, 602-608.
36. 2-M Cell Fraction and Inhibition of Matrigel Invasion, May Predict In Vivo-Selective Antimetastasis Activity of Ruthenium Complexes. J. Pharmacol. Exp. Ther. 2000, 295 927-933.
37. Serli, B.; Iengo, E.; Gianferrara, T.; Zangrando, E.; Alessio, E. Novel Unsymmetrical Ru(III) and Mixed-Valence Ru(III)/Ru(II) Dinuclear Compounds Related to the Antimetastatic Ru(III) Drug NAMI-A. Metal Based Drugs, 2001, 8, 9-18.
38. 2(μ-L) (L = Ditopic, Non-Chelating Aromatic N-Ligand). A Preliminary Investigation. J. Inorg. Biochem. 2000, 79, 173-177.
39. Bergamo, A.; Stocco, G.; Gava, B.; Cocchietto, M.; Alessio, E.; Serli, B.; Iengo, E.; Sava, G. Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines. J. Pharmacol. Exp. Ther. 2003, 305, 725-732.
40. Barca, A.; Pani, B.; Tamaro, M.; Russo, E. Molecular Interactions of Ruthenium Complexes in Isolated Mammalian Cells and Citotoxicity on V79 Cell in Colture. Mutat. Res. 1999, 423, 171-181.
41. Gelasco, A.; Lippard, S. J. Anticancer Activity of Cisplatin and Related Complexes. In Metallopharmaceuticals I-DNA interactions Clarke, M.J.; Sadler, P.J.; Eds.; Springer: Berlin, 1999; pp 1-43.
42. Reedijk, J. New Clues for Platinum Antitumor Chemistry: Kinetically Controlled Metal Binding to DNA. Proc. Natl. Acad. Sci. 2003, 100, 3611-3616.
43. Capozzi, I.; Clerici, K.; Cocchietto, M.; Salerno, G.; Bergamo, A.; Sava, G. Modification of Cell Cycle and Viability of TLX5 Lymphoma In Vitro by Sulfoxide-Ruthenium and Cisplatin Detected by Flow Cytometry. Chem. Biol. Interact. 1998, 113, 51-64.
44. Zhou, B. S.; Elledge, S. J. The DNA Damage Response: Putting Checkpoints in Perspective. Nature 2000, 408, 433-439.
45. Evan, G. I.; Vousden, K. H. Proliferation, Cell Cycle and Apoptosis in Cancer. Nature 2001, 411, 342-348.
46. Hoeijmakers, J. H. Genome Maintenance Mechanisms for Preventig Cancer. Nature 2001, 411, 366-372.
47. 2/M Arrest by the Isoflavone Genistein in Human Prostate Carcinoma Cells. Jpn. J. Cancer Res. 2000, 91, 164-173.
48. 2/M Checkpoint Regulators Cyclin B1 and p34cdc2 in Breast Cancer: a Correlation with Cellular Kinetics. Anticancer Res. 1999, 19, 163-169.
49. Ohi, R.; Gould, K.L. Regulating the Onset of Mitosis. Curr. Opin. Cell. Biol. 1999, 11, 267-273.
50. 2/M Arrest and Skipping of Mitosis in Human Prostate Cell Lines. Cancer Lett. 1999, 138, 121-130.
51. 2 Arrest. Biol. Cell. 1999, 91, 665-674.
52. Heikinheimo, O.; Hsiu, J,G.; Gordon, K.; Kim, S.; Williams, R.F.; Gibbson, W.E.; Hodgen, G.D. Endometrial Effects of RU486 in Primates - Antiproliferative Action Despite Signs of Estrogen Action and Increased Cyclin B Expression. J. Steroid. Biochem. Mol. Biol. 1996, 59, 179-190.
53. Bergamo, A.; Stocco, G.; Casarsa, C.; Cocchietto, M.; Alessio, E.; Serli, B.; Zorzet, S.; Sava, G. Reduction of in Vivo Lung Metastases by Dinuclear Ruthenium Complexes is Coupled to Inhibition of in Vitro Tumor Invasion. Int. J. Oncol. 2003, 24 373-379.
54. Frausin, F.; Cocchietto, M., Bergamo, A.; Scarcia, V.; Furlani, A.; Sava, G. Tumor Cell Uptake of the Metastasis Inhibitor Ruthenium Complex NAMI-A and its in Vitro Effects on KB Cells. Cancer Chemother. Pharmacol. 2002, 50, 405-411.
55. Cocchietto, M.; Zorzet, S.; Sorc, A.; Sava, G. Primary Tumor, Lung and Kidney Retention and Antimetastasis Effect of NAMI-A Following Different Routes of Administration. Invest. New Drugs 2003, 21, 55-62.
56. Hayton, T. W.; Legzdins P.; Sharp, W. B. Coordination and Organometallic Chemistry of Metal - NO Complexes. Chem. Rev. 2002, 102, 935-991.
57. Ziche, M.; Morbidelli, L.; Choudhri, R.; Zhang, H.-T,; Donnini, S.; Granger, H. J.; Bicknell, R. Nitric Oxide Synthase Lies Downstream from Vascular Endothelial Growth Factor-Induced but not Basic Fibroblast Growth Factor-induced Angiogenesis J. Clin. Invest. 1997, 99, 2625-2634.
58. 2+ (1,4,8,11-tetraazacyclotetradecane). Inorg. Chem. 2000, 39 2294-2300.
59. Lopes, L. G. F.; Wieraszko, A.; El-Sherif Y.; Clarke, M. J. The trans-Labilization of Nitric Oxide in Ru(II) Complexes by C-bound Imidazoles. Inorg. Chim. Acta 2001, 312, 15-22.
60. 3 to the Tripeptides gly-gly-gly and gly-gly-his: N-Terminal Amine-Amide and C-Terminal Imidazole-Amide Functionalities in Bidentate Chelation. Inorg. Chim. Acta 2000, 311, 80-94.
61. 2 by Imidazole, Histidine and Iminodiacetate Ligands: a Study of Complexation of "Caged NO" by Simple Bio-Cellular Donors. Transition Met. Chem. 2001, 26, 351-364.
62. Serli, B.; Zangrando, E.; Iengo, E.; Mestroni, G.; Yellowlees, L.; Alessio, E. Synthesis, Structural, Spectroscopic, and Electro-chemical Characterization of Novel Ruthenium-Dimethylsulfoxide Nitrosyls. Inorg. Chem. 2002, 41, 4033-4043.
63. Serli, B.; Zangrando, E.; Gianferrara, T.; Yellowlees, L.; Alessio, E. Coordination and Release of NO by Ruthenium-Dimethylsulfoxide Complexes - Implications for Anti-Metastases Activity. Coord. Chem. Rev. 2003, 245, 73-83.
64. Zangrando, E.; Serli, B.; Yellowlees, L.; Alessio, E. The First Examples of Four and Five O-Bonded Dmso Ligands on a Ruthenium Centre. Dalton Trans 2003, 4391-4392.
65. Sava, G.; Frausin, F.; Cocchietto, M.; Vita, F.; Podda, E.; Spessotto, P.; Furlani, A.; Scarcia, V.; Zabucchi, G. Actin-Dependent Tumour Cell Adhesion After Short-Term Exposure to the Anitmetastasis Ruthenium Complex NAMI-A. Eur. J. Cancer 2004, 40, 1383-1396.
66. Pacor, S.; Zorzet, S.; Cocchietto, M.; Bacac, M.; Vadori, M.; Turrin, C.; Gava, B.; Castellarin, A.; Sava, G. Intra-Tumoral NAMI-A Treatment Triggers Metastasis Reduction, Which Correlates to CD44 Regulation and TIL Recruitment. J. Pharmacol. Exp. Ther. 2004 Apr. 9 [Epub ahead of print].
67. Rademaker-Lakhai, J.M.; van den Bongard, D.; Pluim, D.; Beijnen, J.H.; Schellens, J.H. A Phase I and Pharmacological Study With Imidazolium-trans-DMSO-Imidazole-Tetrachlororuthenate, a Novel Ruthenium Anticancer Agent. Clin. Cancer Res. 2004, 10, 3717-3727.